<DOC>
	<DOCNO>NCT00427362</DOCNO>
	<brief_summary>To assess safety effectiveness adalimumab 40mg treatment PsA unsatisfactory response intolerance prior ongoing DMARDs</brief_summary>
	<brief_title>A Canadian Open-Label Study Evaluate Safety Effectiveness Adalimumab When Added Inadequate Therapy Treatment Psoriatic Arthritis ( PsA ) ( ACCLAIM )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Active psoriatic arthritis define &gt; = 3 tender painful joint &gt; = 3 swollen joint despite standard psoriatic arthritis therapy Has unsatisfactory response intolerance least two prior ongoing DMARDs ( one methotrexate ) Has history cancer certain skin cervical cancer Has history , current acute inflammatory joint disease origin PsA , e.g. , systemic lupus erythematosus etc . Has , unstable disease , include congestive heart failure , inflammatory bowel disease , recent stroke , leg ulcer condition would put subject risk History active tuberculosis , history histoplasmosis listeriosis Latent TB risk factor activation latent TB , e.g . previous exposure TB , initiate TB prophylaxis prior first adalimumab treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>